NTx Bio's Automated mRNA Platform Supports Personalized Cancer Vaccine in Melanoma Trial
NTx Bio, a biomanufacturing technology company based in Rio Rancho, New Mexico, has announced that its NTxscribe® CORE platform is being utilized by researchers at Baylor College of Medicine. This platform is instrumental in manufacturing mRNA for a personalized dendritic cell vaccine (DCV) currently undergoing a Phase 1 clinical trial for refractory melanoma. The trial, sponsored by Diakonos Oncology, marks a significant clinical application of NTx Bio's continuous-flow manufacturing technology. The NTxscribe platform amplifies tumor mRNA derived from small surgical biopsies, a critical step in developing Diakonos Oncology’s DOC1021 (dubodencel) platform. This process ensures that the full-length range of the patient’s tumor transcriptome is maintained, providing a comprehensive representation of tumor antigens for the vaccine. The technology aims to address the challenges of manufacturing consistency in personalized cell and gene therapies, which often involve highly manual processes. 
